Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MYGN vs VCYT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCYT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

VCYT Overall Winner 6-Pillar Tally: MYGN 1 – 5 VCYT Matrix Metrics: MYGN 2 – 8 VCYT

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYGN carries a Unified Composite Score of 46.2/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin).

  • Technical & Structure Timing Caution: MYGN trades in a Markup technical trend (SURGE options phase, RSI 52.1); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MYGN vs VCYT
MYGN NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.57
-1.59% 1D
Market Cap $542.9M
TTM Revenue $804M
Forward P/E 54.0x
Beta / 30D Vol 0.68β · 122% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 30.0 Fund 43.0 Flow 56.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.2% over 20 days), RSI 52
RSI-14: 52.1 · SMA20: $5.94 · SMA50: $4.80
VCYT NASDAQ Head-to-Head Winner
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79

6-Pillar Scorecard Institutional Category Breakdown (MYGN 1 – 5 VCYT)

Columns: Metric · MYGN · VCYT
1. Valuation Multiples VCYT
Forward P/E 54.0x 15.3x
Trailing P/E 54.0x 15.8x
PEG Ratio 1.40x N/M
EV / Revenue 0.8x 3.1x
2. Growth & Scale VCYT
Revenue Growth (YoY) -1.5% +15.1%
Earnings Growth (YoY) +0.0% +58.3%
TTM Revenue (USD) $804M $582M
Market Cap $542.9M $2.0B
3. Profitability & Quality VCYT
Gross Margin 68.3% 74.2%
Operating Margin -13.3% 15.0%
Net Profit Margin -16.1% 21.8%
Return on Equity (ROE) -40.2% 9.4%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) -$38M $162M
Cash Flow Margin -4.7% 27.8%
Net Cash / Leverage $102M Net Debt (0.78x D/E) $159M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VCYT
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 124.6% (22nd %ile) 197.3% (47th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat MYGN
OpEx & R&D Intensity 81.6% of Rev ($656M) 59.2% of Rev ($344M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MYGN (2) vs VCYT (8)
Institutional Metric MYGN VCYT Criterion Row Edge
Market Capitalization
Scale
$542.9M $2.0B Larger Scale VCYT
Trailing P/E Ratio
Valuation
54.0x 15.8x Lower Multiple VCYT
Forward P/E Ratio
Valuation
54.0x 15.3x Lower Multiple VCYT
Revenue Growth (YoY)
Growth
-1.5% +15.1% Higher Growth VCYT
Operating Margin (TTM)
Profitability
-13.3% 15.0% Higher Margin VCYT
Net Profit Margin
Profitability
-16.1% 21.8% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
-40.2% 9.4% Higher ROE VCYT
52-Week Range Position
Momentum
53% ($3–$8) 5% ($22–$61) Stronger Trend MYGN
Beta / 30D Volatility
Risk Regime
0.68β · 122% Vol 3.01β · 199% Vol Lower Realized Risk MYGN
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 49.1 / 100 (HOLD) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$804M $582M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.3% 74.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.40x PEG · 0.8x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$38M ($102M Net Debt (0.78x D/E)) $162M ($159M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYGN +84.27 pp
MYGN: +39.95% · VCYT: -44.32%
3M Horizon MYGN +135.06 pp
MYGN: +94.08% · VCYT: -40.98%
6M Horizon MYGN +94.74 pp
MYGN: +52.6% · VCYT: -42.14%
1Y Horizon MYGN +27.5 pp
MYGN: -12.28% · VCYT: -39.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MYGN Revenue VCYT Revenue MYGN Op. Margin VCYT Op. Margin Margin Leader
FY2018 $740M $90M 16.4% -24.2% MYGN
FY2019 $850M $120M 0.9% -12.6% MYGN
FY2020 $560M $120M -52.0% -30.1% VCYT
FY2021 $690M $220M -27.6% -37.3% MYGN
FY2022 $680M $300M -20.7% -13.9% VCYT
FY2023 $750M $360M -34.2% -23.8% VCYT
FY2024 $840M $450M -14.7% 3.6% VCYT
FY2025 $820M $520M -47.0% 11.2% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MYGN SURGE
12d in phase · OBV DISTRIBUTION
Current IV 124.6%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MYGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MYGN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $542.9M market capitalization and -13.3% operating margin.
OpEx & R&D Reinvestment 81.6% of Rev ($656M)
90D Engineering Disclosures 0 Published
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published

Investor FAQ MYGN vs VCYT Key Questions & Quantitative Answers

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYGN carries a Unified Composite Score of 46.2/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin). Technical & Structure Timing Caution: MYGN trades in a Markup technical trend (SURGE options phase, RSI 52.1); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCYT leads the Growth & Scale pillar: MYGN posts -1.5% YoY revenue growth and +0.0% YoY earnings growth on $804M TTM revenue (68.3% gross margin, -13.3% operating margin), compared with VCYT at +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MYGN cumulative revenue shifted +10.8% while VCYT shifted +477.8%. In operating R&D and SG&A reinvestment, MYGN deploys 81.6% of Rev ($656M) (0 90-day corporate R&D disclosures) versus 59.2% of Rev ($344M) (0 disclosures) for VCYT.

VCYT screens cheaper on headline valuation multiples. MYGN trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.40x PEG, and 0.8x EV/Revenue (-4.7% FCF margin), whereas VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYGN (-40.2% ROE) versus VCYT (9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MYGN carries 124.6% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.68β · 122% Vol realized risk). By comparison, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.